Want to see CATX full AI Analyst Report?
Top Page
Perspective Therapeutics
(CATX)
Select Model
Select Model
Rating:47Neutral
Price Target:
$2.50
▼(-24.01% Downside)
Action:Reiterated
Date:10/08/26
CATX scores low primarily due to very weak current financial performance (minimal/declining revenue, large losses, and heavy cash burn) and a bearish technical setup (price below key moving averages with negative MACD). These negatives are partially offset by a low-debt balance sheet and a constructive earnings update indicating pipeline advancement and a stated cash runway into late 2027, but profitability and cash flow remain the core constraints.
Positive Factors
Regulatory advancement for PSV359
Fast Track Designation provides closer FDA interaction and may streamline development of PSV359 in a rare cancer with limited treatment options. Combined with strong tumor uptake and fast renal clearance in early imaging, the program gains meaningful support for continued clinical advancement.
Negative Factors
Minimal and declining revenue
The company has not established a meaningful revenue base, and the latest decline reinforces its pre-commercial profile. Limited and volatile revenue leaves operating expenses dependent on external funding and means future financial performance remains highly dependent on successful clinical and commercial progression.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory advancement for PSV359
Fast Track Designation provides closer FDA interaction and may streamline development of PSV359 in a rare cancer with limited treatment options. Combined with strong tumor uptake and fast renal clearance in early imaging, the program gains meaningful support for continued clinical advancement.
Read all positive factors
Perspective Therapeutics (CATX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$303.64M
Dividend YieldN/A
Average Volume (3M)2.11M
Price to Earnings (P/E)―
Beta (1Y)1.53
Revenue Growth-66.88%
EPS Growth-0.42%
CountryUS
Employees165
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.56
Shares Outstanding114,151,665
10 Day Avg. Volume2,148,801
30 Day Avg. Volume2,111,481
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-2.13
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue487.72
Enterprise Value/Gross Profit-116.29
Enterprise Value/Ebitda-1.55
Forecast
1Y Price Target
$12.30Price Target Upside273.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.98
Revenue Forecast (FY)$311.69K
Perspective Therapeutics Business Overview & Revenue Model
Company Description
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solution...
Perspective Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
72
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 366.00K | 0.00 | 1.45M | 1.43M | 5.42M | 10.79M |
| Gross Profit | -1.53M | 0.00 | -852.00K | 1.43M | 2.37M | 4.62M |
| EBITDA | -115.07M | -100.80M | -64.49M | -39.95M | -8.47M | -7.14M |
| Net Income | -116.43M | -103.12M | -79.28M | -46.51M | -10.76M | -7.27M |
Balance Sheet | ||||||
| Total Assets | 392.02M | 266.97M | 341.10M | 97.89M | 58.09M | 64.44M |
| Cash, Cash Equivalents and Short-Term Investments | 236.88M | 144.74M | 226.92M | 9.24M | 43.76M | 55.89M |
| Total Debt | 3.96M | 3.25M | 4.06M | 2.55M | 524.00K | 524.00K |
| Total Liabilities | 68.16M | 59.94M | 50.43M | 22.71M | 3.45M | 3.16M |
| Stockholders Equity | 323.86M | 207.03M | 290.67M | 75.18M | 54.64M | 61.28M |
Cash Flow | ||||||
| Free Cash Flow | -121.19M | -95.23M | -72.71M | -37.98M | -10.68M | -7.98M |
| Operating Cash Flow | -93.07M | -82.48M | -18.29M | -36.91M | -10.40M | -7.71M |
| Investing Cash Flow | -52.01M | 41.23M | -218.93M | 24.37M | -28.99M | -284.00K |
| Financing Cash Flow | 164.71M | 10.30M | 289.38M | 785.00K | 28.00K | 56.00K |
Perspective Therapeutics Technical Analysis
Negative
3.29
Price Trends
2.94
Negative
3.10
Negative
3.60
Negative
Market Momentum
-0.11
Negative
46.75
Neutral
59.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CATX, the sentiment is Negative. The current price of 3.29 is above the 20-day moving average (MA) of 2.69, above the 50-day MA of 2.94, and below the 200-day MA of 3.60, indicating a bearish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 46.75 is Neutral, neither overbought nor oversold. The STOCH value of 59.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CATX.
Perspective Therapeutics Risk Analysis
Perspective Therapeutics disclosed 56 risk factors in its most recent earnings report. Perspective Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Perspective Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $229.47M | 20.26 | 23.38% | ― | 15.28% | 53.24% | |
67 Neutral | $362.60M | 25.24 | 10.30% | ― | 25.21% | 6.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $155.12M | -1.25 | -43.59% | ― | 21.96% | -44.65% | |
47 Neutral | $303.64M | -1.70 | -41.56% | ― | -66.88% | -0.42% | |
46 Neutral | $249.99M | -3.12 | 273.71% | ― | 25.25% | -9.85% | |
44 Neutral | $42.26M | -0.31 | -94.35% | ― | 31.52% | -89.07% |
* Healthcare Sector Average
CATX
Perspective Therapeutics
2.66
-2.17
-44.93%
ELMD
Electromed
27.69
3.14
12.79%
QTRX
Quanterix
3.28
-2.60
-44.22%
VMD
Viemed Healthcare
9.52
2.64
38.37%
NNOX
Nano-X Imaging
0.54
-3.52
-86.77%
TLSI
TriSalus Life Sciences
4.06
-0.53
-11.55%
Perspective Therapeutics Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Perspective Therapeutics Wins FDA Fast Track for PSV359
Positive
Oct 8, 2026
On October 8, 2026, Perspective Therapeutics announced that the U.S. Food and Drug Administration granted Fast Track Designation for its investigational FAP-targeted alpha-particle therapy [212Pb]PSV359 in adult patients with locally advanced unre...
Business Operations and StrategyProduct-Related Announcements
Perspective Therapeutics Highlights Progress in Radiopharmaceutical Pipeline
Positive
Oct 1, 2026
On October 1, 2026, Perspective Therapeutics updated its corporate presentation to highlight progress across its three independent clinical-stage 212Pb radiopharmaceutical programs and its broader solid tumor franchise. The new materials underscor...
Business Operations and StrategyProduct-Related Announcements
Perspective Therapeutics, Merck launch radiotherapy-Keytruda collaboration
Positive
Sep 14, 2026
On September 14, 2026, Perspective Therapeutics announced a clinical collaboration and supply agreement with Merck to evaluate its targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda in FAP-α-positive solid tumors. The ...
Business Operations and StrategyProduct-Related Announcements
Perspective Therapeutics Updates Radiopharmaceutical Oncology Pipeline Outlook
Positive
Sep 8, 2026
On September 8, 2026, Perspective Therapeutics, Inc. updated its corporate presentation to showcase progress across three independent clinical-stage radiopharmaceutical programs, all based on 212Pb and aimed at distinct oncology targets. The mater...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Perspective Therapeutics Reports Q2 Results and Pipeline Progress
Positive
Aug 10, 2026
On August 10, 2026, Perspective Therapeutics reported second-quarter 2026 results and recent business milestones, highlighting continued clinical progress across its 212Pb pipeline and preparations for its first Phase 3 trial. The company detailed...
Business Operations and Strategy
Perspective Therapeutics Advances 212Pb Radiopharmaceutical Oncology Platform
Positive
Aug 3, 2026
On August 3, 2026, Perspective Therapeutics updated its corporate presentation highlighting progress across its 212Pb-based oncology portfolio and integrated radiopharmaceutical platform. The materials emphasize a theranostic strategy, regional pr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.